Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
نویسندگان
چکیده
منابع مشابه
Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral anticoagulants (NOACs) that have been compared in clinical trials with existing anticoagulants (warfarin and enoxaparin) in several indications for the prevention and treatment of thrombotic events. All NOACs presented bleeding events despite a careful selection and control of patients. Compared with warfarin,...
متن کاملPractical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants.
OBJECTIVES Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Phase-3 clinical trials demonstrated NOACs were as effective as warfarin in the prevention of stroke or systemic embolism and associated with decreased incidences of intracranial bleeding. Addit...
متن کاملPractical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants
Objectives: Dabigatran, rivaroxaban, apixaban, and edoxaban are nonvitamin K antagonist oral anticoagulants (NOACs) approved for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Phase-3 clinical trials demonstrated NOACs were as effective as warfarin in the prevention of stroke or systemic embolism and associated with decreased incidences of intracranial bleeding. Addi...
متن کاملNonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
Thrombosis is the major common endpoint in most human diseases. In the coronary circulation, occlusive thrombi and/or the rupture of atherosclerotic plaque causes myocar-dial infarction, and in the cerebral circulation thrombosis, causes ischemic stroke. In the venous circulation, venous thromboembolism (VTE), manifesting clinically as pulmonary embolus and deep vein thrombosis (DVT), is a freq...
متن کاملMajor bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.
Vitamin K antagonists are advised in pulmonary arterial hypertension patients despite a lack of safety data. We reviewed major bleeding in three classes of pulmonary hypertension patients, all receiving vitamin K antagonists. Bleeding event rates were 5.4 per 100 patient-years for patients with idiopathic pulmonary arterial hypertension, 19 per 100 patient-years for connective tissue disease re...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BioMed Research International
سال: 2014
ISSN: 2314-6133,2314-6141
DOI: 10.1155/2014/616405